Transaction details
Adam Laponis, Chief Financial Officer of Twist Bioscience Corp (NASDAQ:TWST), sold 4,000 shares of the company’s common stock on April 17, 2026. The shares were disposed of at $60.00 per share, producing proceeds of $240,000. The sale was carried out under a Rule 10b5-1 trading plan that Mr. Laponis adopted on May 8, 2025.
Insider holdings after the sale
Following this transaction, Mr. Laponis directly holds 118,694 shares of Twist Bioscience common stock.
Share price context
The sale comes amid a robust rally for Twist shares, which have climbed 95% year-to-date. The stock is trading at $62.61, noted in company market data as near its 52-week high of $62.09.
Valuation note
InvestingPro analysis included in market commentary classifies the stock as appearing overvalued relative to its Fair Value and lists it among considerations for the Most Overvalued stocks. The note references a comprehensive Pro Research Report on TWST that is one of more than 1,400 available reports designed to convert financial data into investment insights.
Recent operating results
Twist Bioscience reported fiscal 2026 first-quarter results showing revenue of $103.7 million, which exceeded consensus forecasts by 2.96%. The company’s reported earnings per share for the quarter were -$0.50, below the expected -$0.43.
Strategic deals and governance
In a material commercial development, Twist entered into a licensing agreement with Invenra Inc. for the B-Body bispecific antibody platform, under which Twist becomes a co-exclusive provider of the technology. Separately, at the company’s 2026 Annual Meeting shareholders approved director elections and executive compensation, with approximately 91.81% of outstanding shares represented at the meeting.
Analyst and partnership developments
Following Amazon’s launch of its AI-powered Bio Discovery platform, which partners with Twist for drug discovery and design, Guggenheim reiterated a Buy rating on Twist and maintained a $55.00 price target. The collaboration with Amazon integrates Twist’s wet labs into the process to synthesize and test lead candidates. Jefferies also commented on Amazon’s Bio Discovery offering, noting its potential to accelerate research by leveraging more than 40 AI biology models.
What this means in context
The reported insider sale was executed under a pre-existing 10b5-1 plan rather than as an ad-hoc trade. The company’s latest quarter shows mixed financial signals: a modest revenue beat coupled with an EPS shortfall. Concurrently, the licensing agreement with Invenra and the operational tie-up with Amazon’s Bio Discovery platform are recent strategic moves highlighted by analysts and market commentary.
Note on scope: The article reports transaction details, recent financial results, governance outcomes, and partnership activity as disclosed. It does not infer causes beyond the stated facts nor project future performance.